Does native Trypanosoma cruzi calreticulin mediate growth inhibition of a mammary tumor during infection?

Indexación: Web of Science.Background: For several decades now an antagonism between Trypanosoma cruzi infection and tumor development has been detected. The molecular basis of this phenomenon remained basically unknown until our proposal that T. cruzi Calreticulin (TcCRT), an endoplasmic reticulum-resident chaperone, translocated-externalized by the parasite, may mediate at least an important part of this effect. Thus, recombinant TcCRT (rTcCRT) has important in vivo antiangiogenic and antitumor activities. However, the relevant question whether the in vivo antitumor effect of T. cruzi infection is indeed mediated by the native chaperone (nTcCRT), remains open. Herein, by using specific modified anti-rTcCRT antibodies (Abs), we have neutralized the antitumor activity of T. cruzi infection and extracts thereof, thus identifying nTcCRT as a valid mediator of this effect. Methods: Polyclonal anti-rTcCRT F(ab')(2) Ab fragments were used to reverse the capacity of rTcCRT to inhibit EAhy926 endothelial cell (EC) proliferation, as detected by BrdU uptake. Using these F(ab')(2) fragments, we also challenged the capacity of nTcCRT, during T. cruzi infection, to inhibit the growth of an aggressive mammary adenocarcinoma cell line (TA3-MTXR) in mice. Moreover, we determined the capacity of anti-rTcCRT Abs to reverse the antitumor effect of an epimastigote extract (EE). Finally, the effects of these treatments on tumor histology were evaluated. Results: The rTcCRT capacity to inhibit ECs proliferation was reversed by anti-rTcCRT F(ab')(2) Ab fragments, thus defining them as valid probes to interfere in vivo with this important TcCRT function. Consequently, during infection, these Ab fragments also reversed the in vivo experimental mammary tumor growth. Moreover, anti-rTcCRT Abs also neutralized the antitumor effect of an EE, again identifying the chaperone protein as an important mediator of this anti mammary tumor effect. Finally, as determined by conventional histological parameters, in infected animals and in those treated with EE, less invasive tumors were observed while, as expected, treatment with F(ab')(2) Ab fragments increased malignancy. Conclusion: We have identified translocated/externalized nTcCRT as responsible for at least an important part of the anti mammary tumor effect of the chaperone observed during experimental infections with T. cruzi.http://bmccancer.biomedcentral.com/articles/10.1186/s12885-016-2764-

Novel coumarins active against Trypanosoma cruzi and toxicity assessment using the animal model Caenorhabditis elegans

From 2nd Latin American Congress of Clinical and Laboratorial Toxicology Porto Alegre, Brazil. 3-6 June 2018Background: Chagas disease (CD) is a tropical parasitic disease. Although the number of people infected is very high, the only drugs available to treat CD, nifurtimox (Nfx) and benznidazole, are highly toxic, particularly in the chronic stage of the disease. Coumarins are a large class of compounds that display a wide range of interesting biological properties, such as antiparasitic. Hence, the aim of this work is to find a good antitrypanosomal drug with less toxicity. The use of simple organism models has become increasingly attractive for planning and simplifying efficient drug discovery. Within these models, Caenorhabditis elegans has emerged as a convenient and versatile tool with significant advantages for the toxicological potential identification for new compounds. Methods: Trypanocidal activity: Forty-two 4-methylamino-coumarins were assayed against the epimastigote form of Trypanosoma cruzi (Tulahuen 2 strain) by inhibitory concentration 50% (IC50). Toxicity assays: Lethal dose 50% (LD50) and Body Area were determined by Caenorhabditis elegans N2 strain (wild type) after acute exposure. Structure-activity relationship: A classificatory model was built using 3D descriptors. Results: Two of these coumarins demonstrated near equipotency to Nifurtimox (IC50 = 5.0 ± 1 μM), with values of: 11 h (LaSOM 266), (IC50 = 6.4 ± 1 μM) and 11 g (LaSOM 231), (IC50 = 8.2 ± 2.3 μM). In C. elegans it was possible to observe that Nfx showed greater toxicity in both the LD50 assay and the evaluation of the development of worms. It is possible to observe that the efficacy between Nfx and the synthesized compounds (11 h and 11 g) are similar. On the other hand, the toxicity of Nfx is approximately three times higher than that of the compounds. Results from the QSAR-3D study indicate that the volume and hydrophobicity of the substituents have a significant impact on the trypanocidal activities for derivatives that cause more than 50% of inhibition. These results show that the C. elegans model is efficient for screening potentially toxic compounds. Conclusion: Two coumarins (11 h and 11 g) showed activity against T. cruzi epimastigote similar to Nifurtimox, however with lower toxicity in both LD50 and development of C. elegans assays. These two compounds may be a feasible starting point for the development of new trypanocidal drugs

Antibody responses to the RTS,S/AS01E vaccine and plasmodium falciparum antigens after a booster dose within the phase 3 trial in Mozambique

Study of immune correlates against malaria after vaccination with RTS,S/ASO1E: a comphrensive immunological arm of a Phase III double-blind, randomize, controlled multi-centre trial (MAL067).Dades primàries associades a l'article publicat a NPJ Vaccines, vol. 5 [https://doi.org/10.1038/s41541-020-0192-7]The RTS,S/AS01E vaccine has shown consistent but partial vaccine efficacy in a pediatric phase 3 26 clinical trial using a 3-dose immunization schedule. A fourth dose 18 months after the primary 27 vaccination was shown to restore the waning efficacy. However, only total IgG against the 28 immunodominant malaria vaccine epitope has been analyzed following the booster. To better 29 characterize the magnitude, nature and longevity of the immune response to the booster, we 30 measured levels of total IgM, IgG and IgG1-4 subclasses against three constructs of the 31 circumsporozoite protein (CSP) and the hepatitis B surface antigen (HBsAg, also present in RTS,S) 32 by quantitative suspension array technology in 50 subjects in the phase 3 trial in Manhiça, 33 Mozambique. To explore the impact of vaccination on naturally acquired immune responses, we 34 measured antibodies to P. falciparum antigens not included in RTS,S. We found increased IgG, 35 IgG1, IgG3 and IgG4, but not IgG2 nor IgM, levels against vaccine antigens one month after the 4th 36 dose. Overall, antibody responses to the booster dose were lower than the initial peak 37 response to primary immunization and children had higher IgG and IgG1 levels than infants. 38 Higher anti-Rh5 IgG and IgG1-4 levels were detected after the booster dose, suggesting that RTS,S 39 partial protection could increase some blood stage antibody responses. Our work shows that the 40 response to the RTS,S/AS01E booster dose is different from the primary vaccine immune 41 response and highlights the dynamic changes in subclass antibody patterns upon the vaccine 42 booster and with acquisition of adaptive immunity to malaria

Detecting spatio-temporal mortality clusters of European countries by sex and ag

[EN] Background: Mortality decreased in European Union (EU) countries during the last century. Despite these similar trends, there are still considerable differences in the levels of mortality between Eastern and Western European countries. Sub-group analysis of mortality in Europe for different age and sex groups is common, however to our knowledge a spatio-temporal methodology as in this study has not been applied to detect significant spatial dependence and interaction with time. Thus, the objective of this paper is to quantify the dynamics of mortality in Europe and detect significant clusters of mortality between European countries, applying spatio-temporal methodology. In addition, the joint evolution between the mortality of European countries and their neighbours over time was studied. Methods: The spatio-temporal methodology used in this study takes into account two factors: time and the geographical location of countries and, consequently, the neighbourhood relationships between them. This methodology was applied to 26 European countries for the period 1990-2012. Results: Principally, for people older than 64 years two significant clusters were obtained: one of high mortality formed by Eastern European countries and the other of low mortality composed of Western countries. In contrast, for ages below or equal to 64 years only the significant cluster of high mortality formed by Eastern European countries was observed. In addition, the joint evolution between the 26 European countries and their neighbours during the period 1990-2012 was confirmed. For this reason, it can be said that mortality in EU not only depends on differences in the health systems, which are a subject to national discretion, but also on supra-national developments. Conclusions: This paper proposes statistical tools which provide a clear framework for the successful implementation of development public policies to help the UE meet the challenge of rethinking its social model (Social Security and health care) and make it sustainable in the medium term.The authors are grateful for the financial support provided by the Ministry of Economy and Competitiveness, project MTM2013-45381-P. Adina Iftimi gratefully acknowledges financial support from the MECyD (Ministerio de Educacion, Cultura y Deporte, Spain) Grant FPU12/04531. Francisco Montes is grateful for the financial support provided by the Spanish Ministry of Economy and Competitiveness, project MTM2016-78917-R. The research by Patricia Carracedo and Ana Debon has been supported by a grant from the Mapfre Foundation.Carracedo-Garnateo, P.; Debón Aucejo, AM.; Iftimi, A.; Montes-Suay, F. (2018). Detecting spatio-temporal mortality clusters of European countries by sex and ag. International Journal for Equity in Health. 17:1-19. https://doi.org/10.1186/s12939-018-0750-zS11917Anderson TW, Goodman LA. Statistical Inference about Markov Chains. Ann Math Stat. 1957; 28(1):89–110.Anselin L. Local Indicators of Spatial Association–LISA. Geographical Anal. 1995; 27(2):93–115.Bilbao-Ubillos J. Is there still such a thing as the ‘European social model’?. Int J Soc Welf. 2016; 25:110–25.Bivand R. spdep: Spatial Dependence:Weighting Schemes, Statistics and Models. 2012. R package version 0.5-53. http://CRAN.R-project.org/package=spdep .Bivand R, Hauke J, Kossowski T. Computing the Jacobian in Gaussian Spatial Autoregressive Models: An Illustrated Comparison of Available Methods. Geographical Anal. 2013; 45(2):150–79.Bivand R, Keitt T, Rowlingson B. rgdal: Bindings for the Geospatial Data Abstraction Library. 2016. R package version 1.1-10. https://CRAN.R-project.org/package=rgdal .Bivand R, Lewin-Koh N. maptools: Tools for Reading and Handling Spatial Objects. 2016. R package version 0.8-39 https://CRAN.R-project.org/package=maptools .Bonneux L, Huisman C. de Beer J. Mortality in 272 European regions, 2002-2004: an update. Eur J Epidemiol. 2010; 25(1):77–85. Reporting year: 2010.Charpentier A. Computational Actuarial Science with R. Chapman y Hall/CRC. 2014.Cliff AD, Ord JK. Spatial autocorrelation. London: Pion; 1973.Cutler D, Deaton A, Lleras-Muney A. The Determinants of Mortality. J Econ Perspect. 2006; 20(3):97–120.Debón A, Chaves L, Haberman S, Villa F. Characterization of between-group inequality of longevity in European Union countries. Insur Math Econ. 2017; 75:151–65.Fleiss J, Levin B, Paik M. Statistical Methods for Rates and Proportions: Wiley; 2013.Gordon M. Gmisc: Descriptive Statistics, Transition Plots, and More. 2016. R package version 1.3.1. https://CRAN.R-project.org/package=Gmisc .Hinde A. Demographic methods. Routledge: Routledge; 1998.Hyndman RJ, Booth H, Tickle L, Maindonald J. demography: Forecasting mortality, fertility, migration and population data. 2014. package version 1.18. https://CRAN.R-project.org/package=demography .Human Mortality Database. University of California, Berkeley (USA), and Max Planck Institute for Demographic Research (Germany). 2016. Available at www.mortality.org or www.humanmortality.de (data downloaded on 12th July 2016).Hatzopoulos P, Haberman S. Common mortality modeling and coherent forecasts. An empirical analysis of worldwide mortality data. Insurance Math Econ. 2013; 52(2):320–37.Iftimi A, Montes F, Santiyán AM, Martínez-Ruiz F. Space–time airborne disease mapping applied to detect specific behaviour of varicella in Valencia, Spain Spatial Spatio-Temporal Epidemiol. 2015; 14:33–44.Julious S, Nicholl J, George S. Why do we continue to use standardized mortality ratios for small area comparisons?. J Public Health. 2001; 23(1):40–6.Laurent T, Ruiz-Gazen A, Thomas-Agnan C. GeoXp: An R package for exploratory spatial data analysis. J Stat Softw. 2012; 47(2):1–23.Leon DA. Trends in European life expectancy: a salutary view. Int J Epidemiol. 2011; 40:271–7.Li H, Li L, Wu B, Xiong Y. The End of Cheap Chinese Labor. J Econ Perspect. 2013; 26(4):57–74.Mackenbach JP, Karanikolos M, McKee M. The unequal health of Europeans: successes and failures of policies. The Lancet. 2013; 381(9872):1125–34.Meslé F. Mortality in Central and Eastern Europe: Long-term trends and recent upturns. Demographic Res. 2004; 2:45–70.Meslé F, Vallin J. Mortality in Europe: The divergence between East and West. Population (English Edition). 2002; 57(1):157–97.Moran PAP. Notes on continuous stochastic phenomena. Biometrika. 1950; 37(1-2):17–23.Moran PAP. A Test for the Serial Independence of Residuals. Biometrika. 1950; 37(1/2):178–81.Neuwirth E. RColorBrewer: ColorBrewer Palettes. R package version. 2014; 1:1–2. https://CRAN.R-project.org/package=RColorBrewer .Oleckno WA. Epidemiology: concepts and methods: Waveland Press, Inc.; 2008.Quah D. Galton’s Fallacy and Tests of the Convergence Hypothesis. Scand J Econ. 1993; 95(4):427–43.R Core Team. R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing. 2015. https://www.R-project.org/ .Rey S. In: Fischer MM, Nijkamp P, (eds).Spatial Dynamics and Space-Time Data Analysis. Berlin, Heidelberg: Springer: Handbook of Regional Science; 2014, pp. 1365–83.Rey SJ. Spatial Empirics for Economic Growth and Convergence. Geogr Anal. 2001; 33(3):195–214.Riffe T. Reading Human Fertility Database and Human Mortality Database data into R. Technical Report TR-2015-004, MPIDR. 2015.Schofield R, Reher D, Bideau A. The Decline of Mortality in Europe. International studies in demography. Oxford: Clarendon Press; 1991.Shaw M, Orford S, Brimblecombe N, Dorling D. Widening inequality in mortality between 160 regions of 15 European countries in the early 1990s. Soc Sci Med. 2000; 50(7-8):1047–58.Spinakis A, Anastasiou G, Panousis V, Spiliopoulos K, Palaiologou S, Yfantopoulos J. Expert Review and Proposals for Measurement of Health Inequalities in the European Union. European Commission. Technical report,Luxembourg: European Commission Directorate General for Health and Consumers; 2011. http://ec.europa.eu/health/social_determinants/docs/full_quantos_en.pdf .Staehr K. Economic transition in Estonia. Background, reforms and results In: Rindzeviciute E, editor. Contemporary Change in Estonia. Baltic and East European Studies. Sodertorns hogskola: Baltic and East European Studies: 2004. p. 437–67.Trnka L, Dankova D, Zitova J, Cimprichova L, Migliori GB, Clancy L, Zellweger J. Survey of BCG vaccination policy in Europe: 1994-96. Bull World Health Organ. 1998; 76(1):85–91.United Nations Inter–agency Group for Child Mortality Estimation. Levels & Trends in Child Mortality: Report 2013. New York: Technical report, United Nations Children’s Fund; 2013. Avaliable at www.who.int/maternal_child_adolescent/documents/levels_trends_child_mortality_2013.pdf Accessed 27 Oct 2016.Vågerö D. The east–west health divide in Europe: Growing and shifting eastwards. Eur Rev. 2010; 18(01):23–34.Vaupel JW, Zhang Z, van Raalte AA, Vaupel JW, Zhang Z, van Raalte AA. Life expectancy and disparity: an international comparison of life table data. BMJ Open. 2011; 1:e000128.Wickham H, Chang W. devtools: Tools to Make Developing R Packages Easier. R package version 1.11.1. 2016. https://CRAN.R-project.org/package=devtools .Wilcox R. Introduction to robust estimation and hypothesis testing, 3rd Edition.San Diego: Academic Press; 2012

RTS,S/AS01E immunization increases antibody responses to vaccine-unrelated Plasmodium falciparum antigens associated with protection against clinical malaria in African children:a case-control study

BACKGROUND: Vaccination and naturally acquired immunity against microbial pathogens may have complex interactions that influence disease outcomes. To date, only vaccine-specific immune responses have routinely been investigated in malaria vaccine trials conducted in endemic areas. We hypothesized that RTS,S/A01E immunization affects acquisition of antibodies to Plasmodium falciparum antigens not included in the vaccine and that such responses have an impact on overall malaria protective immunity. METHODS: We evaluated IgM and IgG responses to 38 P. falciparum proteins putatively involved in naturally acquired immunity to malaria in 195 young children participating in a case-control study nested within the African phase 3 clinical trial of RTS,S/AS01E (MAL055 NCT00866619) in two sites of different transmission intensity (Kintampo high and Manhiça moderate/low). We measured antibody levels by quantitative suspension array technology and applied regression models, multimarker analysis, and machine learning techniques to analyze factors affecting their levels and correlates of protection. RESULTS: RTS,S/AS01E immunization decreased antibody responses to parasite antigens considered as markers of exposure (MSP142, AMA1) and levels correlated with risk of clinical malaria over 1-year follow-up. In addition, we show for the first time that RTS,S vaccination increased IgG levels to a specific group of pre-erythrocytic and blood-stage antigens (MSP5, MSP1 block 2, RH4.2, EBA140, and SSP2/TRAP) which levels correlated with protection against clinical malaria (odds ratio [95% confidence interval] 0.53 [0.3-0.93], p = 0.03, for MSP1; 0.52 [0.26-0.98], p = 0.05, for SSP2) in multivariable logistic regression analyses. CONCLUSIONS: Increased antibody responses to specific P. falciparum antigens in subjects immunized with this partially efficacious vaccine upon natural infection may contribute to overall protective immunity against malaria. Inclusion of such antigens in multivalent constructs could result in more efficacious second-generation multistage vaccines

Network Centrality of Metro Systems

Whilst being hailed as the remedy to the world’s ills, cities will need to adapt in the 21st century. In particular, the role of public transport is likely to increase significantly, and new methods and technics to better plan transit systems are in dire need. This paper examines one fundamental aspect of transit: network centrality. By applying the notion of betweenness centrality to 28 worldwide metro systems, the main goal of this paper is to study the emergence of global trends in the evolution of centrality with network size and examine several individual systems in more detail. Betweenness was notably found to consistently become more evenly distributed with size (i.e. no “winner takes all”) unlike other complex network properties. Two distinct regimes were also observed that are representative of their structure. Moreover, the share of betweenness was found to decrease in a power law with size (with exponent 1 for the average node), but the share of most central nodes decreases much slower than least central nodes (0.87 vs. 2.48). Finally the betweenness of individual stations in several systems were examined, which can be useful to locate stations where passengers can be redistributed to relieve pressure from overcrowded stations. Overall, this study offers significant insights that can help planners in their task to design the systems of tomorrow, and similar undertakings can easily be imagined to other urban infrastructure systems (e.g., electricity grid, water/wastewater system, etc.) to develop more sustainable cities

Erratum: Author Correction: Antibody responses to the RTS,S/AS01E vaccine and Plasmodium falciparum antigens after a booster dose within the phase 3 trial in Mozambique.

[This corrects the article DOI: 10.1038/s41541-020-0192-7.]